(Date:10/6/2008)...pecial supplement of the Oct. 15,journal Cancer fo...iddle-income countries to implement breast cancer ...se among women worldwide., "Guidelines for Intern...ntation" developed by the Breast Health Global Ini...e allocation -- based on countries,overall econom...
(Date:10/6/2008)...ently posted detailed information on its Cimzia in... side effects caused by the drug and its family kn...side effects are the development of fatal infectio...hild patients. , Denver, ...r one resource for everything and anything legal o...
(Date:10/6/2008)...ased civil litigation and criminal defense firm re...y awarded $3.2 million to plaintiff earlier this y...nd ((Lexis Nexis) October 6, 2008 -- Attorneys in ...Murtha & Psoras] have successfully resolved a ... welder who was awarded more than $3 million by a ...
(Date:10/5/2008)...elp detect serious bacterial infections (SBIs) lik...ions in young infants who come to the emergency de.... Researchers at Children,s Hospital Boston, colla...niversity, show that a new diagnostic marker calle...risk for SBIs while potentially reducing unnecessa...
Breaking Medicine News(10 mins):Health News:International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer 2Health News:International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer 3Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 3Health News:Miller, Murtha & Psoras Secures Multimillion-Dollar Settlement for Victim of Industrial Accident at Bethlehem Steel 2Health News:New test could help catch serious infections in babies 2(Date:10/6/2008)...l Associations Collaborate to Improve Patient Safe... The American College of,Cardiology in collaborati...nd the American Heart Association today released c...for reducing the risk of ulcers and,gastrointestin...,anti-inflammatory drugs (NSAIDs) along with antip...
(Date:10/6/2008)... Calif. and SEATTLE, Oct. 6 /- Comple...on human genome sequencing,company, and the Instit...r,partnership to conduct populationwide human geno...e Genomics will use its proprietary,DNA sequencing...provided by,ISB. Then, once proof-of-concept has b...
(Date:10/6/2008)...6 /- Dendreon Corporation (...onday, October 6, 2008 at 9:00 AM,ET (6:00 AM PT) ...ts IMPACT,(IMmunotherapy for Prostate AdenoCarcino... of PROVENGE(R) (sipuleucel-T), the Company,s inve...treatment of advanced prostate,cancer., Those ...
(Date:10/3/2008)...ober 3 /- Amsterdam Molecul...ield of human gene therapy,announced today that i...Marketing Authorization Application (MAA) for Glyb... seriously debilitating and potentially lethal,dis... clinical studies (22,patients in total) demonstra...
Breaking Medicine Technology:Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use 2Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use 3Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use 4Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study 2Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2AMT Intends to Incorporate Additional Data to its Marketing Authorization Dossier for Glybera(R) 2AMT Intends to Incorporate Additional Data to its Marketing Authorization Dossier for Glybera(R) 3Biophysical Unveils BiophysicalCheck Health Assessment Program to Aid in Pre Symptomatic Detection of Disease 10231 1Biophysical Unveils BiophysicalCheck Health Assessment Program to Aid in Pre Symptomatic Detection of Disease 10231 2Biophysical Unveils BiophysicalCheck Health Assessment Program to Aid in Pre Symptomatic Detection of Disease 10231 3Wrigley Keeps Kids Smiling Through Donation to American Dental Association Program 10227 1Wrigley Keeps Kids Smiling Through Donation to American Dental Association Program 10227 2Wrigley Keeps Kids Smiling Through Donation to American Dental Association Program 10227 3Wrigley Keeps Kids Smiling Through Donation to American Dental Association Program 10227 4Mark Ostrowski Joins GenVault as Vice President of Sales and Marketing 2763 1Mark Ostrowski Joins GenVault as Vice President of Sales and Marketing 2763 2Arbor Surgical Technologies Announces Series C Financing and Licensing Agreement with Medtronic 2759 1Arbor Surgical Technologies Announces Series C Financing and Licensing Agreement with Medtronic 2759 2...ON, N.J.--(BUSINESS WIRE)--Apr 26, 2007 - Columbia... that preliminary,results from the ongoing data an...bo-controlled, double-blind Phase III clinical,tri...revention of,preterm birth in women with a previou...s revealed a possible effect of PROCHIEVE 8%,in de...
... Australia, April 26, 2007 /PRNewswire-FirstCall/ ...mited today,announced preliminary results from its...th metastatic colorectal cancer, where,Alchemia,s ...s,considered to be a cornerstone drug for the trea...eing made at a preliminary stage of,the analysis i...
Other Medicine Technology:Columbia Laboratories Reports Preliminary Findings from the Ongoing,Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%,(progesterone gel) to Prevent Preterm Birth 2Columbia Laboratories Reports Preliminary Findings from the Ongoing,Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%,(progesterone gel) to Prevent Preterm Birth 3Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 2Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 3Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 4Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 5Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 6Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 7This new dedicated VICTOR2 model is for fluorescence and luminescence measurements.
VICTOR2 V measures prompt fluorescence, fluorescence polarization, luminescence, time-resolved fluorescence and absorbance. This model includes high density TRF (for 1536-well plates), temperature
This a new dedicated VICTOR2 model for fluorescence and luminescence detection with stacker and robotic loading.
The basic modular version of the VICTOR2 multilabel counter for fluorescence, luminescence and absorption measurements, with the stacker and the robotic loading configuration.
Medicine Products: